Korea Investment CORP acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 214,100 shares of the company’s stock, valued at approximately $7,112,000.

Several other institutional investors have also added to or reduced their stakes in TEVA. Sei Investments Co. increased its stake in Teva Pharmaceutical Industries Limited by 103.6% in the second quarter. Sei Investments Co. now owns 1,721,466 shares of the company’s stock worth $57,188,000 after buying an additional 875,789 shares in the last quarter. Ingalls & Snyder LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the second quarter worth approximately $272,000. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares in the last quarter. Tufton Capital Management increased its stake in Teva Pharmaceutical Industries Limited by 6.0% in the second quarter. Tufton Capital Management now owns 40,328 shares of the company’s stock worth $1,340,000 after buying an additional 2,295 shares in the last quarter. Finally, Sterling Investment Management Inc. purchased a new stake in Teva Pharmaceutical Industries Limited during the second quarter worth approximately $1,969,000. 56.27% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (TEVA) opened at 17.19 on Friday. The company’s market cap is $17.47 billion. The company has a 50-day moving average price of $30.08 and a 200 day moving average price of $31.67. Teva Pharmaceutical Industries Limited has a 52 week low of $17.12 and a 52 week high of $55.39.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.25 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.39 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.98%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

COPYRIGHT VIOLATION WARNING: “214,100 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by Korea Investment CORP” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/214100-shares-in-teva-pharmaceutical-industries-limited-nyseteva-acquired-by-korea-investment-corp/1472896.html.

A number of equities research analysts recently commented on the company. Zacks Investment Research downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 target price (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Jefferies Group LLC reiterated a “hold” rating and issued a $26.00 target price (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price (down from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Three research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and an average target price of $37.69.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.